Clinical Trial: Letrozole combined with famitinib for the treatment of platinum-resistant recurrent ovarian cancer with high estrogen receptor expression: A multicenter, open-label, randomized controlled phase II clinical trial (China)

China, Oct. 9 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Letrozole combined with famitinib for the treatment of platinum-resistant recurrent ovarian cancer with high estrogen receptor expression: A multicenter, open-label, randomized controlled phase II clinical trial'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133887

Registration Time: 2026/10/09

Type: Interventional study

Primary Sponsor: Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=337209

Published by HT Digital Content Services with permission from Health Daily Digest....